Joseph Kim, MD
Associate Professor of Internal Medicine (Medical Oncology)Cards
Additional Titles
Director, Prostate Cancer Research
Lecture Coordinator in Hematology/Oncology, Yale Affiliated Hospital Program
Contact Info
About
Copy Link
Titles
Associate Professor of Internal Medicine (Medical Oncology)
Director, Prostate Cancer Research; Lecture Coordinator in Hematology/Oncology, Yale Affiliated Hospital Program
Biography
Dr. Joseph Kim is a board-certified medical oncologist and a Director of the Prostate Cancer Research Program for Prostate and Urological Cancers DART of Yale Cancer Center. He is a recipient of the Cancer Clinical Investigator Team Leadership Award from the National Cancer Institute (NCI) and a recipient of other awards from Conquer Cancer Foundation of the American Society of Clinical Oncology (ASCO). Dr. Kim has led several peer-reviewed, NCI-sponsored, investigator-initiated clinical trials in prostate cancer, bladder cancer, and other solid tumors as a study chair.
Dr. Joseph Kim serves as an author/editor of the genitourinary (GU) cancers chapter of ASCO-SEP, an educational textbook for medical oncologists, and a co-editor of the GU cancers section of a peer-reviewed journal, Current Oncology Report, and ad hoc reviewer of multiple oncology journals. He has been invited as a speaker for numerous international and national academic conferences including GU Cancers Symposium, ASCO Annual Meeting, CTEP/ NCI meeting, ASCO Direct highlights, International Genitourinary Cancer Conference, and many others.
His passion lies in delivering compassionate, patient-centered, and evidence-based care for patients with genitourinary cancer including prostate cancer, bladder, and other urinary tract cancer, testicular cancer, and penile cancer. He is also passionate about developing and executing hypothesis-driven clinical trials of novel therapies in GU cancers and other solid tumors.
Appointments
Medical Oncology and Hematology
Associate Professor on TermPrimary
Other Departments & Organizations
- All Institutions
- Cancer Signaling Networks
- Early Phase Clinical Trial Program
- Internal Medicine
- Medical Oncology and Hematology
- Prostate & Urologic Cancers Program
- Yale Cancer Center
- Yale New Haven Health System
Education & Training
- Fellow
- National Institutes of Health (2013)
- Resident
- Emory University School of Medicine (2010)
- MD
- Wake Forest University School of Medicine (2007)
- BA
- Covenant College, Biology, Pre-Medicine (2001)
Research
Copy Link
Overview
Clinical Trials - Early Phase; Cancer therapies; Androgen Receptor, DNA Repair Pathways; mTOR pathways; Cancer immunotherapy
ORCID
0000-0003-2222-3531
Research at a Glance
Yale Co-Authors
Publications Timeline
Daniel P. Petrylak, MD
Insoo Kang, MD
Joseph Paul Eder, MD
Patricia LoRusso, DO
Jennefer Par-Young
Joseph Vinetz, MD, FACP, FIDSA, FASTMH, BS
Publications
2026
Nezastomig (anti-PSMA×CD28) with or without cemiplimab (anti–PD-1) in patients with metastatic castration-resistant prostate cancer (mCRPC) or metastatic clear cell renal cell carcinoma (mccRCC): A phase 1/2 study.
Siddiqui B, Stein M, Zhang J, Falchook G, Twardowski P, Gao X, Kim J, Gelmann E, Carneiro B, Wise D, Gartrell B, Bowman I, Dreicer R, Govindraj S, Thanigaimani P, Fang F, Seebach F, Kinnaman M, Sandigursky S, Miller E. Nezastomig (anti-PSMA×CD28) with or without cemiplimab (anti–PD-1) in patients with metastatic castration-resistant prostate cancer (mCRPC) or metastatic clear cell renal cell carcinoma (mccRCC): A phase 1/2 study. Journal Of Clinical Oncology 2026, 44: tps296-tps296. DOI: 10.1200/jco.2026.44.7_suppl.tps296.Peer-Reviewed Original ResearchConceptsMetastatic castration-resistant prostate cancerProstate-specific membrane antigenDose-escalation phaseProstate-specific antigenComposite response rateRadiographic responseSystemic therapyPrimary endpointProstate cancerEscalation phaseMCRPC cohortProstate Cancer Working Group 3 criteriaAnti-programmed cell death 1Rate of prostate-specific antigenMetastatic clear cell renal cell carcinomaAndrogen receptor signaling inhibitorsClinical activityMalignancy associated with poor prognosisT-cell immune checkpointsEvidence of clinical activityT cell-mediated tumor killingCastration-resistant prostate cancerImmune-mediated adverse reactionsClear cell renal cell carcinomaAnti-PD-1
2025
A phase 1/2 study of nezastomig (anti-PSMA×CD28) with or without cemiplimab (anti–PD-1) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and clear cell renal cell carcinoma (ccRCC).
Siddiqui B, Carneiro B, Stein M, Zhang J, Kelly W, Wise D, Tsao K, Falchook G, Twardowski P, Gao X, Kim J, Gelmann E, Thanigaimani P, Fang F, Seebach F, Lowy I, Ingham M, Kinnaman M, Sandigursky S, Miller E. A phase 1/2 study of nezastomig (anti-PSMA×CD28) with or without cemiplimab (anti–PD-1) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and clear cell renal cell carcinoma (ccRCC). Journal Of Clinical Oncology 2025, 43: tps293-tps293. DOI: 10.1200/jco.2025.43.5_suppl.tps293.Peer-Reviewed Original ResearchCitationsConceptsMetastatic castration-resistant prostate cancerProstate-specific membrane antigenPhase 1/2 studyMetastatic ccRCCClinical activityDose escalationSystemic therapyProstate cancerT cellsAndrogen receptor signaling inhibitorsEvidence of clinical activityProstate-specific antigen levelCastration-resistant prostate cancerAnti-PD-1Castration-resistant diseasePhase 2 doseDose-escalation phaseCell renal cell carcinomaPSMA-expressing cellsTyrosine kinase inhibitorsRenal cell carcinomaFirst-in-humanProstate cancer cellsLong-term outcomesFirst-in-class
2024
Circulating Tumor DNA Dynamics Fail to Predict Efficacy of Poly(ADP-ribose) Polymerase/VEGFR Inhibition in Patients With Heavily Pretreated Advanced Solid Tumors
Hu Y, Narayan A, Xu Y, Wolfe J, Vu D, Trinh T, Kantak C, Ivy S, Eder J, Deng Y, LoRusso P, Kim J, Patel A. Circulating Tumor DNA Dynamics Fail to Predict Efficacy of Poly(ADP-ribose) Polymerase/VEGFR Inhibition in Patients With Heavily Pretreated Advanced Solid Tumors. JCO Precision Oncology 2024, 8: e2300289. PMID: 38412387, PMCID: PMC10914240, DOI: 10.1200/po.23.00289.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsCell-free circulating tumor DNANon-small-cell lung cancerSmall-cell lung cancerTriple-negative breast cancerPancreatic ductal adenocarcinomaAdvanced solid tumorsVariant allele fractionRadiographic responseOverall survivalCombination therapySolid tumorsCtDNA levelsLung cancerPretreated advanced solid tumorsDays of combination therapyMetastatic pancreatic ductal adenocarcinomaResponse to anticancer therapyAssociated with disease progressionProgression-free survivalPlasma samplesLead-InPoly(ADP-riboseInferior OSTumor DNASurvival outcomes
2022
Effect of Androgen–Androgen Receptor Directed Therapy on COVID-19 Outcome in Prostate Cancer Patients
Ünlü S, Shin J, Par-Young J, Simonov M, Vinetz J, Petrylak D, Kang I, Kim J. Effect of Androgen–Androgen Receptor Directed Therapy on COVID-19 Outcome in Prostate Cancer Patients. Cancer Investigation 2022, 41: 77-83. PMID: 36373994, DOI: 10.1080/07357907.2022.2139839.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsProstate cancer patientsCOVID-19 outcomesCancer patientsPoor COVID-19 outcomesAndrogen-androgen receptorExpression of TMPRSS2COVID-19 infectionSARS-CoV-2Directed therapyMean hospitalizationPCa patientsHospitalization ratesPCa casesRetrospective analysisOutcome differencesPatientsDefinitive conclusionsStatistical significanceData generate hypothesesHospitalizationTherapyTMPRSS2Cellular entryOutcomesARDTRandomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984
Kim JW, McKay RR, Radke MR, Zhao S, Taplin ME, Davis NB, Monk P, Appleman LJ, Lara PN, Vaishampayan UN, Zhang J, Paul AK, Bubley G, Van Allen EM, Unlu S, Huang Y, Loda M, Shapiro GI, Glazer PM, LoRusso PM, Ivy SP, Shyr Y, Swisher EM, Petrylak DP. Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984. Journal Of Clinical Oncology 2022, 41: 871-880. PMID: 36256912, PMCID: PMC9901975, DOI: 10.1200/jco.21.02947.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsMetastatic castration-resistant prostate cancerRadiographic progression-free survivalMedian radiographic progression-free survivalCastration-resistant prostate cancerArm AProstate cancerAdverse eventsGrade 3Progressive metastatic castration-resistant prostate cancerEndothelial growth factor receptor inhibitorEnd pointHomologous recombination repair genesGrowth factor receptor inhibitorsPrimary end pointSecondary end pointsProgression-free survivalRecombination repair genesPoly (ADP-ribose) polymerase inhibitionTreat setTreat patientsClinical outcomesRandomized trialsPreclinical modelsReceptor inhibitorsCediranibEmerging Role of PARP Inhibitors in Metastatic Prostate Cancer
Unlu S, Kim JW. Emerging Role of PARP Inhibitors in Metastatic Prostate Cancer. Current Oncology Reports 2022, 24: 1619-1631. PMID: 35931885, DOI: 10.1007/s11912-022-01305-0.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsPARP inhibitorsBRCA2 mutationsProstate cancerFDA approvalMetastatic prostate cancer patientsAccelerated FDA approvalDeleterious BRCA2 mutationsHRR gene mutationsObjective response ratePhase II studyMetastatic prostate cancerProstate cancer patientsPoly (ADP-ribose) polymerase (PARP) inhibitorsUS FDA approvalSomatic mutationsMCRPC patientsCombination regimenII studyClinical benefitRadium-223Cancer patientsStandard treatmentAndrogen receptorDNA damage repair pathwaysClinical developmentEffect of androgen receptor directed therapy in prostate cancer patients with COVID-19.
Unlu S, Shin J, Par-Young J, Vinetz J, Petrylak D, Kang I, Kim J. Effect of androgen receptor directed therapy in prostate cancer patients with COVID-19. Journal Of Clinical Oncology 2022, 40: 161-161. DOI: 10.1200/jco.2022.40.6_suppl.161.Peer-Reviewed Original ResearchConceptsProstate cancerPCa patientsAndrogen receptorCOVID-19Mortality rateYale New Haven Health SystemProtective rolePrevalence of PCaRate of hospitalRetrospective chart reviewExpression of TMPRSS2Rate of hospitalizationProstate cancer patientsAndrogen receptor antagonistProstate cancer casesSARS-CoV-2Institutional review boardDirected therapyChart reviewClinical characteristicsGnRH agonistHormone therapyGnRH antagonistHome medicationsClinical outcomes
2021
Digital Health for Optimal Supportive Care in Oncology: Benefits, Limits, and Future Perspectives
Aapro M, Bossi P, Dasari A, Fallowfield L, Gascón P, Geller M, Jordan K, Kim J, Martin K, Porzig S. Digital Health for Optimal Supportive Care in Oncology: Benefits, Limits, and Future Perspectives. Kompass Nutrition & Dietetics 2021, 1: 72-90. DOI: 10.1159/000519151.Peer-Reviewed Original ResearchCitationsAltmetricConceptsSupportive careDigital health solutionsHealth solutionsHealth economic endpointsOncology supportive careRoutine supportive careHealthcare resource utilizationOptimal supportive careImprovement of QOLTreatment of symptomsPatient-centered careEvidence-based therapeutic interventionsDifferent healthcare systemsUnplanned hospitalizationMost patientsSymptom supportOncology practiceSymptom distressClinical studiesPatient managementOral drugsSymptom monitoringPatient complianceTreatment efficacyTherapeutic interventionsClinical Activity and Safety of Cediranib and Olaparib Combination in Patients with Metastatic Pancreatic Ductal Adenocarcinoma without BRCA Mutation
Kim J, Cardin DB, Vaishampayan UN, Kato S, Grossman SR, Glazer P, Shyr Y, Ivy SP, LoRusso P. Clinical Activity and Safety of Cediranib and Olaparib Combination in Patients with Metastatic Pancreatic Ductal Adenocarcinoma without BRCA Mutation. The Oncologist 2021, 26: e1104-e1109. PMID: 33742489, PMCID: PMC8265343, DOI: 10.1002/onco.13758.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsMetastatic pancreatic adenocarcinomaHomologous recombination DNA repair deficiencyMetastatic pancreatic ductal adenocarcinomaPancreatic ductal adenocarcinomaOlaparib combinationStable diseaseBRCA mutationsAdverse eventsDuctal adenocarcinomaCommon treatment-related adverse eventsVascular endothelial growth factor receptor inhibitorEndothelial growth factor receptor inhibitorTreatment-related adverse eventsGrowth factor receptor inhibitorsPrior systemic chemotherapyMedian overall survivalObjective response rateGermline BRCA mutationsBest overall responseExpression of BRCA1/2Restaging scanCancer cell linesPrimary endpointStudy drugSystemic chemotherapySapanisertib, a dual mTORC1/2 inhibitor, for TSC1- or TSC2- mutated metastatic urothelial carcinoma (mUC).
Kim J, Milowsky M, Hahn N, Kwiatkowski D, Morgans A, Davis N, Appleman L, Gupta S, Lara P, Hoffman-Censits J, Quinn D, Shyr Y, LoRusso P, Sklar J, Petrylak D. Sapanisertib, a dual mTORC1/2 inhibitor, for TSC1- or TSC2- mutated metastatic urothelial carcinoma (mUC). Journal Of Clinical Oncology 2021, 39: 431-431. DOI: 10.1200/jco.2021.39.6_suppl.431.Peer-Reviewed Original ResearchCitationsConceptsMetastatic urothelial carcinomaStable diseaseAdverse eventsObjective responseWithdrew consentTSC2 mutationsUrothelial carcinomaTSC1 mutationsTumor samplesCommon adverse eventsMedian overall survivalTreatment-related deathsPhase II studyCentral labOverall response rateDual mTORC1/2 inhibitorUnknown mutational statusCentral confirmationEligible patientsEvaluable patientsMUC patientsRestaging scanII studyPrimary endpointBaseline characteristics
Clinical Trials
Current Trials
A Phase 1/1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and anti-tumor activity of PF-07220060 as a Single Agent and as Part of Combination Therapy in Participants with Advanced Solid tumors (WIRB)
IRB ID2000029000RoleSub InvestigatorPrimary Completion Date09/23/2026Recruiting ParticipantsA Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination With Immuno-Oncology Agents in Subjects With Unresectable Advanced or Metastatic Solid Tumors
IRB ID2000033292RoleSub InvestigatorPrimary Completion Date02/01/2026Recruiting ParticipantsA Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients With Advanced Solid Tumors Harboring a p53 Y220C Mutation (PYNNACLE)
IRB ID2000032119RoleSub InvestigatorPrimary Completion Date03/17/2026Recruiting ParticipantsA Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies With KRAS G12D Mutation
IRB ID2000032188RoleSub InvestigatorPrimary Completion Date10/31/2026Recruiting ParticipantsPhase Ib/II Study of ZEN003694 and Entinostat in Advanced and Refractory Solid Tumors and Lymphomas
IRB ID2000033256RoleSub InvestigatorPrimary Completion Date07/01/2025Recruiting Participants
Academic Achievements & Community Involvement
Copy Link
Activities
activity ASCO-SEP
11/01/2021 - PresentJournal ServiceEditoractivity Current Oncology Reports
02/01/2015 - PresentJournal ServiceEditoractivity Frontiers Oncology
07/01/2019 - PresentJournal ServiceRevieweractivity American Society of Clinical Oncology
07/05/2010 - PresentProfessional OrganizationsMemberactivity Society of Immunotherapy of Cancer
07/01/2013 - PresentProfessional OrganizationsMember
Honors
honor Cancer Clinical Investigator Team Leadership Award (CCITLA)
08/02/2021National AwardNCIDetailsUnited Stateshonor Young Investigator Award
06/02/2013International AwardConquer Cancer Foundation, American Society of Clinical OncologyDetailsUnited Stateshonor Merit Award
02/14/2013International AwardConqer Cancer Foundation, American Society of Clinical OncologyDetailsUnited States
News & Links
Copy Link
News
- March 23, 2026
Yale Launches Innovative Clinical Trial for Metastatic Bladder Cancer
- February 23, 2024
Department of Internal Medicine Promotions and Appointments (February 2024)
- August 11, 2023
Study Shows Promise of Immunotherapy Treatment for Penile Cancer
- June 11, 2023
Profiles in Survivorship: John Bova
Related Links
Get In Touch
Copy Link